Quiver AI Summary
BridgeBio Pharma, Inc. announced new data highlighting the kidney-protective benefits of acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), in a publication in Circulation: Heart Failure. The analyses showed that acoramidis treatment resulted in a rapid reversible dip in estimated glomerular filtration rate (eGFR) and a significant reduction in urinary albumin to creatinine ratio (UACR) by Day 28, with both measures indicating improved kidney function. Sustained benefits through Month 30 included an improved chronic eGFR slope and continued UACR reduction. Acoramidis appeared to operate similarly to established kidney-targeting medications, which is unprecedented among current ATTR-CM therapies. Further findings suggested that the acute eGFR dip correlated positively with better cardiovascular outcomes, potentially offering protection to both heart and kidney functions. These results signify a meaningful advancement in the treatment of patients with ATTR-CM, where kidney dysfunction is a major concern linked to increased mortality risk.